The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
|Articles|October 15, 2016
- BioPharm International-10-15-2016
- Volume 2016 eBook
- Issue 2
Evaluating Technology and Innovation in Biopharmaceutical Manufacturing
A technology management process identifies and evaluates new technologies in biopharmaceutical manufacturing to aid business decisions.
Advertisement
Manufacturing equipment, technologies, and processes need to constantly evolve. Technical personnel from Janssen Supply Chain (JSC) and consultants from KPMG's Global Strategy Group discuss a technology management process to identify and evaluate new technologies in biopharmaceutical manufacturing to aid business decisions and improve supply chain capabilities.
Articles in this issue
almost 10 years ago
Cell Line Quality Technologiesalmost 10 years ago
Investigation Effectiveness Drives Human Performance Excellencealmost 10 years ago
Data Integrity Challenges in Manufacturingalmost 10 years ago
Seeking Accelerated Biosimilar Characterizationalmost 10 years ago
Plant-Made Pharmaceuticals—Accelerating Drug Development Globallyalmost 10 years ago
Testing the BrothAdvertisement
Related to this article
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Patients suffered pyrogenic reactions before Fresenius Kabi recalled 3 contaminated batches at its 430,000-sq-ft Melrose Park, Ill., biologics plant.
More than half of patients achieved clear or almost clear hands and feet with lebrikizumab by week 16, and 77% reported satisfaction with clearance.
NouvSight001 isn't limited to the RPE65-mutation subset current gene therapy treats, potentially reaching more of the 1.5 million with RP worldwide.
Updated 36-month data in 15 high-dose patients showed 80% slowing on cUHDRS, while the 48-month cUHDRS result did not reach statistical significance. uniQure attributes the gap to attrition in the external control, and the FDA is reviewing a BLA based on the 36-month data.
Guselkumab eased spinal pain, stiffness, and MRI-confirmed spinal inflammation in a 411-patient trial of psoriatic arthritis with axial involvement.
Dr Stephen Wilson, CEO of the Botnar Institute of Immune Engineering, describes Basel's collaborative ecosystem and a 3-year roadmap linking research to global clinical partners.
Advertisement
Advertisement